470 related articles for article (PubMed ID: 7905543)
1. Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas.
Bongiorno PF; Whyte RI; Lesser EJ; Moore JH; Orringer MB; Beer DG
J Thorac Cardiovasc Surg; 1994 Feb; 107(2):590-5. PubMed ID: 7905543
[TBL] [Abstract][Full Text] [Related]
2. Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu.
Hakim AA; Barry CP; Barnes HJ; Anderson KE; Petitte J; Whitaker R; Lancaster JM; Wenham RM; Carver DK; Turbov J; Berchuck A; Kopelovich L; Rodriguez GC
Cancer Prev Res (Phila); 2009 Feb; 2(2):114-21. PubMed ID: 19174584
[TBL] [Abstract][Full Text] [Related]
3. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.
Kern JA; Slebos RJ; Top B; Rodenhuis S; Lager D; Robinson RA; Weiner D; Schwartz DA
J Clin Invest; 1994 Feb; 93(2):516-20. PubMed ID: 7906694
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of potential oncogene alterations in the ENU1564 rat mammary tumor model.
Hal DG; Stoica G
Anticancer Res; 1994; 14(2A):481-7. PubMed ID: 7912494
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking.
Westra WH; Offerhaus GJ; Goodman SN; Slebos RJ; Polak M; Baas IO; Rodenhuis S; Hruban RH
Am J Surg Pathol; 1993 Mar; 17(3):213-20. PubMed ID: 8434702
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Bcl-2 and mutations in p53 and K-ras in resected human non-small cell lung cancers.
Kitagawa Y; Wong F; Lo P; Elliott M; Verburgt LM; Hogg JC; Daya M
Am J Respir Cell Mol Biol; 1996 Jul; 15(1):45-54. PubMed ID: 8679221
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic analysis of k-ras, p53, and ERBB-2 gene alterations in pulmonary adenocarcinoma.
Visscher DW; Yadrandji S; Tabaczka P; Kraut M; Sarkar FH
Diagn Mol Pathol; 1997 Feb; 6(1):64-9. PubMed ID: 9028739
[TBL] [Abstract][Full Text] [Related]
9. Molecular markers for diagnostic cytology of neoplasms in the head region of the pancreas: mutation of K-ras and overexpression of the p53 protein product.
van Es JM; Polak MM; van den Berg FM; Ramsoekh TB; Craanen ME; Hruban RH; Offerhaus GJ
J Clin Pathol; 1995 Mar; 48(3):218-22. PubMed ID: 7730480
[TBL] [Abstract][Full Text] [Related]
10. Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma.
Rall CJ; Yan YX; Graeme-Cook F; Beauchamp R; Yandell DW; Povoski SP; Rustgi AK
Pancreas; 1996 Jan; 12(1):10-7. PubMed ID: 8927612
[TBL] [Abstract][Full Text] [Related]
11. Relationship of family cancer history to the expression of p53, p21WAF-1, HER-2/neu, and K-ras mutation in pancreatic adenocarcinoma.
Dergham ST; Dugan MC; Arlauskas P; Du W; Vaitkevicius VK; Crissman JD; Sarkar FH
Int J Pancreatol; 1997 Jun; 21(3):225-34. PubMed ID: 9322121
[TBL] [Abstract][Full Text] [Related]
12. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
[TBL] [Abstract][Full Text] [Related]
13. Do molecular markers predict survival in non-small-cell lung cancer?
Greatens TM; Niehans GA; Rubins JB; Jessurun J; Kratzke RA; Maddaus MA; Niewoehner DE
Am J Respir Crit Care Med; 1998 Apr; 157(4 Pt 1):1093-7. PubMed ID: 9563724
[TBL] [Abstract][Full Text] [Related]
14. Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins.
Vatan O; Bilaloglu R; Tunca B; Cecener G; Gebitekin C; Egeli U; Yakut T; Urer N
Tumori; 2007; 93(5):473-7. PubMed ID: 18038880
[TBL] [Abstract][Full Text] [Related]
15. Molecular analysis of p53 and K-ras in lung carcinomas of coal miners.
Sarkar FH; Li Y; Vallyathan V
Int J Mol Med; 2001 Oct; 8(4):453-9. PubMed ID: 11562787
[TBL] [Abstract][Full Text] [Related]
16. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.
Kawesha A; Ghaneh P; Andrén-Sandberg A; Ograed D; Skar R; Dawiskiba S; Evans JD; Campbell F; Lemoine N; Neoptolemos JP
Int J Cancer; 2000 Nov; 89(6):469-74. PubMed ID: 11102889
[TBL] [Abstract][Full Text] [Related]
17. p53, erbB-2 and K-ras gene alterations are rare in spontaneous and plutonium-239-induced canine lung neoplasia.
Tierney LA; Hahn FF; Lechner JF
Radiat Res; 1996 Feb; 145(2):181-7. PubMed ID: 8606928
[TBL] [Abstract][Full Text] [Related]
18. Analysis of K-ras, p53 and c-raf-1 mutations in beryllium-induced rat lung tumors.
Nickell-Brady C; Hahn FF; Finch GL; Belinsky SA
Carcinogenesis; 1994 Feb; 15(2):257-62. PubMed ID: 7545909
[TBL] [Abstract][Full Text] [Related]
19. Role of proto-oncogene activation in carcinogenesis.
Anderson MW; Reynolds SH; You M; Maronpot RM
Environ Health Perspect; 1992 Nov; 98():13-24. PubMed ID: 1486840
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma.
Dergham ST; Dugan MC; Kucway R; Du W; Kamarauskiene DS; Vaitkevicius VK; Crissman JD; Sarkar FH
Int J Pancreatol; 1997 Apr; 21(2):127-43. PubMed ID: 9209954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
